Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Huarte, E; Sarobe, P; Lasarte, JJ; Brem, G; Weiss, EH; Prieto, J; Borras-Cuesta, F
   Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen
   INTERNATIONAL JOURNAL OF CANCER
   
   E. Huarte et al., "Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen", INT J CANC, 97(1), 2002, pp. 58-63
2. Zeh, HJ; Stavely-O'Carroll, K; Choti, MA
   Vaccines for colorectal cancer
   TRENDS IN MOLECULAR MEDICINE
   
   H.J. Zeh et al., "Vaccines for colorectal cancer", TRENDS MO M, 7(7), 2001, pp. 307-313
3. Nawrocki, S; Wysocki, PJ; Mackiewicz, A
   Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer
   EXPERT OPINION ON BIOLOGICAL THERAPY
   
   S. Nawrocki et al., "Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer", EXPERT OP B, 1(2), 2001, pp. 193-204
4. Wang, E; Phan, GQ; Marincola, FM
   T-cell-directed cancer vaccines: the melanoma model
   EXPERT OPINION ON BIOLOGICAL THERAPY
   
   E. Wang et al., "T-cell-directed cancer vaccines: the melanoma model", EXPERT OP B, 1(2), 2001, pp. 277-290
5. Fishman, M; Seigne, J; Antonia, S
   Novel therapies for renal cell carcinoma
   EXPERT OPINION ON INVESTIGATIONAL DRUGS
   
   M. Fishman et al., "Novel therapies for renal cell carcinoma", EXPERT OP I, 10(6), 2001, pp. 1033-1044
6. Matzku, S; Zoller, M
   Specific immunotherapy of cancer in elderly patients
   DRUGS & AGING
   
   S. Matzku e M. Zoller, "Specific immunotherapy of cancer in elderly patients", DRUG AGING, 18(9), 2001, pp. 639-664
7. Fagnoni, FF; Della Cuna, GR
   Immunotherapy: On the edge between experimental and clinical oncology
   JOURNAL OF CHEMOTHERAPY
   
   F.F. Fagnoni e G.R. Della Cuna, "Immunotherapy: On the edge between experimental and clinical oncology", J CHEMOTHER, 13(1), 2001, pp. 15-23
8. Poloso, N; Nagarajan, S; Bumgarner, GW; Zampell, JC; Selvaraj, P
   Designer cancer vaccines made easy: Protein transfer of immunostimulatory molecules for use in therapeutic tumor vaccines
   FRONTIERS IN BIOSCIENCE
   
   N. Poloso et al., "Designer cancer vaccines made easy: Protein transfer of immunostimulatory molecules for use in therapeutic tumor vaccines", FRONT BIOSC, 6, 2001, pp. D760-D775
9. Gerard, CM; Baudson, N; Kraemer, K; Ledent, C; Pardoll, D; Bruck, C
   Recombinant human papillomavirus type 16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic mice
   CLINICAL CANCER RESEARCH
   
   C.M. Gerard et al., "Recombinant human papillomavirus type 16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic mice", CLIN CANC R, 7(3), 2001, pp. 838S-847S
10. Maecker, HT; Auffermann-Gretzinger, S; Nomura, LE; Liso, A; Czerwinski, DK; Levy, R
    Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry
    CLINICAL CANCER RESEARCH
    
    H.T. Maecker et al., "Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry", CLIN CANC R, 7(3), 2001, pp. 902S-908S
11. Sicard, H; Al Saati, T; Delsol, G; Fournie, JJ
    Synthetic phosphoantigens enhance human V gamma 9V delta 2 T lymphocytes killing of non-Hodgkin's B lymphoma
    MOLECULAR MEDICINE
    
    H. Sicard et al., "Synthetic phosphoantigens enhance human V gamma 9V delta 2 T lymphocytes killing of non-Hodgkin's B lymphoma", MOL MED, 7(10), 2001, pp. 711-722
12. Liso, A; Benedetti, R; Flenghi, L; Falini, B
    Vaccine therapy of B cell malignancies: Different strategies for a novel approach
    LEUKEMIA & LYMPHOMA
    
    A. Liso et al., "Vaccine therapy of B cell malignancies: Different strategies for a novel approach", LEUK LYMPH, 42(5), 2001, pp. 881-889
13. Agrawal, SG; Marquet, J; Plumas, J; Rouard, H; Delfau-Larue, MH; Gaulard, P; Boumsell, L; Reyes, F; Bensussan, A; Farcet, JP
    Multiple co-stimulatory signals are required for triggering proliferation of T cells from human secondary lymphoid tissue
    INTERNATIONAL IMMUNOLOGY
    
    S.G. Agrawal et al., "Multiple co-stimulatory signals are required for triggering proliferation of T cells from human secondary lymphoid tissue", INT IMMUNOL, 13(4), 2001, pp. 441-450
14. Renner, C; Kubuschok, B; Trumper, L; Pfreundschuh, M
    Clinical approaches to vaccination in oncology
    ANNALS OF HEMATOLOGY
    
    C. Renner et al., "Clinical approaches to vaccination in oncology", ANN HEMATOL, 80(5), 2001, pp. 255-266
15. Weth, R; Christ, O; Stevanovic, S; Zoller, M
    Gene delivery by attenuated Salmonella typhimurium: Comparing the efficacyof helper versus cytotoxic T cell priming in tumor vaccination
    CANCER GENE THERAPY
    
    R. Weth et al., "Gene delivery by attenuated Salmonella typhimurium: Comparing the efficacyof helper versus cytotoxic T cell priming in tumor vaccination", CANC GENE T, 8(8), 2001, pp. 599-611
16. Rousseau, RF; Hirschmann-Jax, C; Takahashi, S; Brenner, MK
    Cancer vaccines
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    
    R.F. Rousseau et al., "Cancer vaccines", HEMAT ONCOL, 15(4), 2001, pp. 741
17. Renkvist, N; Castelli, C; Robbins, PF; Parmiani, G
    A listing of human tumor antigens recognized by T cells
    CANCER IMMUNOLOGY IMMUNOTHERAPY
    
    N. Renkvist et al., "A listing of human tumor antigens recognized by T cells", CANCER IMMU, 50(1), 2001, pp. 3-15
18. Westermann, J; Reich, G; Kopp, J; Haus, U; Dorken, D; Pezzutto, A
    Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study
    CANCER IMMUNOLOGY IMMUNOTHERAPY
    
    J. Westermann et al., "Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study", CANCER IMMU, 49(11), 2001, pp. 613-620
19. Streeter, PR; Minster, NI; Kahn, LE; Hood, WF; Vickery, LE; Thurman, TL; Monahan, JB; Welply, JK; McKearn, JP; Woulfe, SL
    Progenipoietins: Biological characterization of a family of dual agonists of fetal liver tyrosine kinase-3 and the granulocyte colony-stimulating factor receptor
    EXPERIMENTAL HEMATOLOGY
    
    P.R. Streeter et al., "Progenipoietins: Biological characterization of a family of dual agonists of fetal liver tyrosine kinase-3 and the granulocyte colony-stimulating factor receptor", EXP HEMATOL, 29(1), 2001, pp. 41-50
20. Siemens, DR; Ratliff, TL
    Vaccines in urologic malignancies
    UROLOGICAL RESEARCH
    
    D.R. Siemens e T.L. Ratliff, "Vaccines in urologic malignancies", UROL RES, 29(3), 2001, pp. 152-162
21. Moingeon, P
    Cancer vaccines
    VACCINE
    
    P. Moingeon, "Cancer vaccines", VACCINE, 19(11-12), 2001, pp. 1305-1326
22. Robert, C
    Immunotherapy for melanoma: how can tolerance be overcome?
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
    
    C. Robert, "Immunotherapy for melanoma: how can tolerance be overcome?", ANN DER VEN, 128(6-7), 2001, pp. 709-713
23. Gravekamp, C
    Tailoring cancer vaccines to the elderly: the importance of suitable mousemodels
    MECHANISMS OF AGEING AND DEVELOPMENT
    
    C. Gravekamp, "Tailoring cancer vaccines to the elderly: the importance of suitable mousemodels", MECH AGE D, 122(11), 2001, pp. 1087-1105
24. Schultze, JL; Maecker, B; von Bergwelt-Baildon, MS; Anderson, KS; Vongerheide, RH
    Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens
    VOX SANGUINIS
    
    J.L. Schultze et al., "Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens", VOX SANGUIN, 80(2), 2001, pp. 81-89
25. Glaser, A; Schuler-Thurner, B; Feuerstein, B; Zingsem, J; Zimmermann, R; Weisbach, V; Eckstein, R
    Collection of MNCs with two cell separators for adoptive immunotherapy in patients with stage IV melanoma
    TRANSFUSION
    
    A. Glaser et al., "Collection of MNCs with two cell separators for adoptive immunotherapy in patients with stage IV melanoma", TRANSFUSION, 41(1), 2001, pp. 117-122
26. Malmberg, KJ; Arulampalam, V; Ichihara, F; Petersson, M; Seki, K; Andersson, T; Lenkei, R; Masucci, G; Pettersson, S; Kiessling, R
    Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappa B activation
    JOURNAL OF IMMUNOLOGY
    
    K.J. Malmberg et al., "Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappa B activation", J IMMUNOL, 167(5), 2001, pp. 2595-2601
27. Keogh, E; Fikes, J; Southwood, S; Celis, E; Chesnut, R; Sette, A
    Identification of new epitopes from four different tumor-associated antigens: Recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity
    JOURNAL OF IMMUNOLOGY
    
    E. Keogh et al., "Identification of new epitopes from four different tumor-associated antigens: Recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity", J IMMUNOL, 167(2), 2001, pp. 787-796
28. Zoller, M; Christ, O
    Prophylactic tumor vaccination: Comparison of effector mechanisms initiated by protein versus DNA vaccination
    JOURNAL OF IMMUNOLOGY
    
    M. Zoller e O. Christ, "Prophylactic tumor vaccination: Comparison of effector mechanisms initiated by protein versus DNA vaccination", J IMMUNOL, 166(5), 2001, pp. 3440-3450
29. Tangri, S; Ishioka, GY; Huang, XQ; Sidney, J; Southwood, S; Fikes, S; Sette, A
    Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide
    JOURNAL OF EXPERIMENTAL MEDICINE
    
    S. Tangri et al., "Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide", J EXP MED, 194(6), 2001, pp. 833-846
30. Kessler, JH; Beekman, NJ; Bres-Vloemans, SA; Verdijk, P; van Veelen, PA; Kloosterman-Joosten, AM; Vissers, DCJ; ten Bosch, GJA; Kester, MGD; Sijts, A; Drijfhout, JW; Ossendorp, F; Offringa, R; Melief, CJM
    Efficient identification of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis
    JOURNAL OF EXPERIMENTAL MEDICINE
    
    J.H. Kessler et al., "Efficient identification of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis", J EXP MED, 193(1), 2001, pp. 73-88
31. Veelken, H
    Tumor vaccination via the use of monoclonal antibodies
    INTERNIST
    
    H. Veelken, "Tumor vaccination via the use of monoclonal antibodies", INTERNIST, 42(6), 2001, pp. 874-883
32. Gjertsen, MK; Buanes, T; Rosseland, AR; Bakka, A; Gladhaug, I; Soreide, O; Eriksen, JA; Moller, M; Baksaas, I; Lothe, RA; Saeterdal, I; Gaudernack, G
    Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma
    INTERNATIONAL JOURNAL OF CANCER
    
    M.K. Gjertsen et al., "Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma", INT J CANC, 92(3), 2001, pp. 441-450
33. Benlalam, H; Labarriere, N; Linard, B; Derre, L; Diez, E; Pandolfino, MC; Bonneville, M; Jotereau, F
    Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy
    EUROPEAN JOURNAL OF IMMUNOLOGY
    
    H. Benlalam et al., "Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy", EUR J IMMUN, 31(7), 2001, pp. 2007-2015
34. Kobayashi, H; Lu, J; Celis, E
    Identification of helper T-cell epitopes that encompass or lie proximal tocytotoxic T-cell epitopes in the gp100 melanoma tumor antigen
    CANCER RESEARCH
    
    H. Kobayashi et al., "Identification of helper T-cell epitopes that encompass or lie proximal tocytotoxic T-cell epitopes in the gp100 melanoma tumor antigen", CANCER RES, 61(20), 2001, pp. 7577-7584
35. Brossart, P; Schneider, A; Dill, P; Schammann, T; Grunebach, F; Wirths, S; Kanz, L; Buhring, HJ; Brugger, W
    The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-Lymphocytes
    CANCER RESEARCH
    
    P. Brossart et al., "The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-Lymphocytes", CANCER RES, 61(18), 2001, pp. 6846-6850
36. Trojan, A; Witzens, M; Schultze, JL; Vonderheide, RH; Harig, S; Krackhardt, AM; Stahel, RA; Gribben, JG
    Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule
    CANCER RESEARCH
    
    A. Trojan et al., "Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule", CANCER RES, 61(12), 2001, pp. 4761-4765
37. Ravaud, A
    Cell therapy for solid tumors
    BULLETIN DU CANCER
    
    A. Ravaud, "Cell therapy for solid tumors", B CANCER, 88(1), 2001, pp. 91-100
38. Armstrong, A; Dermime, S
    Developing effective cancer vaccines: design and monitoring are critical
    BRITISH JOURNAL OF CANCER
    
    A. Armstrong e S. Dermime, "Developing effective cancer vaccines: design and monitoring are critical", BR J CANC, 84(11), 2001, pp. 1433-1436
39. Tanaka, H; Tsunoda, T; Nukaya, I; Sette, A; Matsuda, K; Umano, Y; Yamaue, H; Takesako, K; Tanimura, H
    Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2/neu: possible immunotherapy for colorectal carcinomas
    BRITISH JOURNAL OF CANCER
    
    H. Tanaka et al., "Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2/neu: possible immunotherapy for colorectal carcinomas", BR J CANC, 84(1), 2001, pp. 94-99
40. McAfee, JG
    The impact of recent advances in immunology and cancer therapy on nuclear medicine
    SEMINARS IN NUCLEAR MEDICINE
    
    J.G. McAfee, "The impact of recent advances in immunology and cancer therapy on nuclear medicine", SEM NUC MED, 31(4), 2001, pp. 342-349
41. Tjoa, BA; Murphy, GP
    Progress in active specific immunotherapy of prostate cancer
    SEMINARS IN SURGICAL ONCOLOGY
    
    B.A. Tjoa e G.P. Murphy, "Progress in active specific immunotherapy of prostate cancer", SEM SURG ON, 18(1), 2000, pp. 80-87
42. Carmon, L; Tzehoval, E; Tirosh, B; el-Shami, KM; Bar-Haim, E; Vadai, E; Feldman, M; Eisenbach, L
    Anti-tumor vaccination in heterozygous congenic F1 mice: Presentation of tumor-associated antigen by the two parental class I alleles
    JOURNAL OF IMMUNOTHERAPY
    
    L. Carmon et al., "Anti-tumor vaccination in heterozygous congenic F1 mice: Presentation of tumor-associated antigen by the two parental class I alleles", J IMMUNOTH, 23(3), 2000, pp. 344-352
43. Ressing, ME; van Driel, WJ; Brandt, RMP; Kenter, GG; de Jong, JH; Bauknecht, T; Fleuren, GJ; Hoogerhout, P; Offringa, R; Sette, A; Celis, E; Grey, H; Trimbos, BJ; Kast, WM; Melief, CJM
    Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma
    JOURNAL OF IMMUNOTHERAPY
    
    M.E. Ressing et al., "Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma", J IMMUNOTH, 23(2), 2000, pp. 255-266
44. Swiniarski, H; Wolf, SF; Sturmhoefel, K; Peterson, RL; Dorner, AJ; O'Toole, M
    IL-12-dependent enhancement of CTL response to weak class I-restricted peptide immunogens requires coimmunization with T helper cell immunogens
    CLINICAL IMMUNOLOGY
    
    H. Swiniarski et al., "IL-12-dependent enhancement of CTL response to weak class I-restricted peptide immunogens requires coimmunization with T helper cell immunogens", CLIN IMMUNO, 94(3), 2000, pp. 200-211
45. Strong, TV
    Gene therapy for carcinoma of the breast - Genetic immunotherapy
    BREAST CANCER RESEARCH
    
    T.V. Strong, "Gene therapy for carcinoma of the breast - Genetic immunotherapy", BREAST CA R, 2(1), 2000, pp. 15-21
46. Pietersz, GA; Apostolopoulos, V; McKenzie, IFC
    Generation of cellular immune responses to antigenic tumor peptides
    CELLULAR AND MOLECULAR LIFE SCIENCES
    
    G.A. Pietersz et al., "Generation of cellular immune responses to antigenic tumor peptides", CELL MOL L, 57(2), 2000, pp. 290-310
47. Tjoa, BA; Salgaller, ML
    Progress in active-specific immunotherapy of brain malignancies
    EXPERT OPINION ON INVESTIGATIONAL DRUGS
    
    B.A. Tjoa e M.L. Salgaller, "Progress in active-specific immunotherapy of brain malignancies", EXPERT OP I, 9(9), 2000, pp. 2093-2101
48. Karanikas, V; Lodding, J; Maino, VC; McKenzie, IFC
    Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy
    CLINICAL CANCER RESEARCH
    
    V. Karanikas et al., "Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy", CLIN CANC R, 6(3), 2000, pp. 829-837
49. Batra, RK; Sharma, S; Dubinett, SM
    New gene and cell-based therapies for lung cancer
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
    
    R.K. Batra et al., "New gene and cell-based therapies for lung cancer", SEM RESP CR, 21(5), 2000, pp. 463-472
50. Dubinett, SM; Batra, RK; Miller, PW; Sharma, S
    Tumor antigens in thoracic malignancy
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
    
    S.M. Dubinett et al., "Tumor antigens in thoracic malignancy", AM J RESP C, 22(5), 2000, pp. 524-527
51. Chaperot, L; Jacob, MC; Molens, JP; Manches, O; Bensa, JC; Plumas, J
    From the study of tumor cell immunogenicity to the generation of antitumorcytotoxic cells in non-Hodgkin's lymphomas
    LEUKEMIA & LYMPHOMA
    
    L. Chaperot et al., "From the study of tumor cell immunogenicity to the generation of antitumorcytotoxic cells in non-Hodgkin's lymphomas", LEUK LYMPH, 38(3-4), 2000, pp. 247
52. Brinckerhoff, LH; Thompson, LW; Slingluff, GL
    Melanoma vaccines
    CURRENT OPINION IN ONCOLOGY
    
    L.H. Brinckerhoff et al., "Melanoma vaccines", CURR OPIN O, 12(2), 2000, pp. 163-173
53. Sinkovics, JG; Horvath, JC
    Vaccination against human cancers
    INTERNATIONAL JOURNAL OF ONCOLOGY
    
    J.G. Sinkovics e J.C. Horvath, "Vaccination against human cancers", INT J ONCOL, 16(1), 2000, pp. 81-96
54. Kim, TS; Chung, SW; Kim, SH; Kang, BY; Hwang, SY; Lee, JW
    Genetically engineered fibroblasts with antigen-presenting capability: Efficient induction of an antigen-specific cytotoxic T-lymphocyte response andprotection against tumor development in vivo
    CANCER GENE THERAPY
    
    T.S. Kim et al., "Genetically engineered fibroblasts with antigen-presenting capability: Efficient induction of an antigen-specific cytotoxic T-lymphocyte response andprotection against tumor development in vivo", CANC GENE T, 7(6), 2000, pp. 861-869
55. Nabeta, Y; Sahara, H; Suzuki, K; Kondo, H; Nagata, M; Hirohashi, Y; Sato, Y; Wada, Y; Sato, T; Wada, T; Yamashita, T; Kikuchi, K; Sato, N
    Induction of cytotoxic T lymphocytes from peripheral blood of human histocompatibility antigen (HLA)-A31(+) gastric cancer patients by in vitro stimulation with antigenic peptide of signet ring cell carcinoma
    JAPANESE JOURNAL OF CANCER RESEARCH
    
    Y. Nabeta et al., "Induction of cytotoxic T lymphocytes from peripheral blood of human histocompatibility antigen (HLA)-A31(+) gastric cancer patients by in vitro stimulation with antigenic peptide of signet ring cell carcinoma", JPN J CANC, 91(6), 2000, pp. 616-621
56. Bendandi, M
    Anti-idiotype vaccines for human follicular lymphoma
    LEUKEMIA
    
    M. Bendandi, "Anti-idiotype vaccines for human follicular lymphoma", LEUKEMIA, 14(8), 2000, pp. 1333-1339
57. Dietrich, PY; Walker, PR
    Tumour tolerance and immune scape to apoptosis
    M S-MEDECINE SCIENCES
    
    P.Y. Dietrich e P.R. Walker, "Tumour tolerance and immune scape to apoptosis", M S-MED SCI, 16(4), 2000, pp. 492-499
58. Bremers, AJA; Kuppen, PJK; Parmiani, G
    Tumour immunotherapy: the adjuvant treatment of the 21st century?
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY
    
    A.J.A. Bremers et al., "Tumour immunotherapy: the adjuvant treatment of the 21st century?", EUR J SUR O, 26(4), 2000, pp. 418-424
59. Meidenbauer, N; Harris, DT; Spitler, LE; Whiteside, TL
    Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer
    PROSTATE
    
    N. Meidenbauer et al., "Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer", PROSTATE, 43(2), 2000, pp. 88-100
60. Avigan, D; Wu, Z; Joyce, R; Elias, A; Richardson, P; McDermott, D; Levine, J; Kennedy, L; Giallombardo, N; Hurley, D; Gong, J; Kufe, D
    Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer
    BONE MARROW TRANSPLANTATION
    
    D. Avigan et al., "Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer", BONE MAR TR, 26(2), 2000, pp. 169-176
61. Apostolopoulos, V; Barnes, N; Pietersz, GA; McKenzie, IFC
    Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses
    VACCINE
    
    V. Apostolopoulos et al., "Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses", VACCINE, 18(27), 2000, pp. 3174-3184
62. Kim, TS; Chung, SW; Hwang, SY
    Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7.1 and interleukin-7
    VACCINE
    
    T.S. Kim et al., "Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7.1 and interleukin-7", VACCINE, 18(25), 2000, pp. 2886-2894
63. Bartholeyns, J; Bardot, V; Chokri, M; Romet-Lemonne, JL
    Adoptive immunotherapy: present status and perspectives in cancer treatment.
    REVUE DE MEDECINE INTERNE
    
    J. Bartholeyns et al., "Adoptive immunotherapy: present status and perspectives in cancer treatment.", REV MED IN, 21(10), 2000, pp. 863-871
64. Shlyakhovenko, VA
    Modern trends in cancer vaccinotherapy
    EXPERIMENTAL ONCOLOGY
    
    V.A. Shlyakhovenko, "Modern trends in cancer vaccinotherapy", EXP ONCOL, 22(3), 2000, pp. 99-109
65. Curiel-Lewandrowski, C; Demierre, MF
    Advances in specific immunotherapy of malignant melanoma
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
    
    C. Curiel-Lewandrowski e M.F. Demierre, "Advances in specific immunotherapy of malignant melanoma", J AM ACAD D, 43(2), 2000, pp. 167-185
66. Kim, CH; Todoroki, T; Matsumura, M; Ohno, T
    Eligibility of antigenic-peptide-pre-loaded and fixed adhesive peripheral blood cells for induction of cytotoxic T lymphocytes from cancer patients with elevated serum levels of carcinoembryonic antigen
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    
    C.H. Kim et al., "Eligibility of antigenic-peptide-pre-loaded and fixed adhesive peripheral blood cells for induction of cytotoxic T lymphocytes from cancer patients with elevated serum levels of carcinoembryonic antigen", J CANC RES, 126(7), 2000, pp. 383-390
67. Tsuge, T; Yamakawa, M; Tsukamoto, M
    Infiltrating dendritic/Langerhans cells in primary breast cancer
    BREAST CANCER RESEARCH AND TREATMENT
    
    T. Tsuge et al., "Infiltrating dendritic/Langerhans cells in primary breast cancer", BREAST CANC, 59(2), 2000, pp. 141-152
68. Tartour, E; Fridman, WH
    Cancer vaccines 2000
    IMMUNOLOGY LETTERS
    
    E. Tartour e W.H. Fridman, "Cancer vaccines 2000", IMMUNOL LET, 74(1), 2000, pp. 1-3
69. Kerr, DJ; Midgley, RS
    Immunotherapy for colorectal cancer: Potential application in an adjuvant setting
    SEMINARS IN ONCOLOGY
    
    D.J. Kerr e R.S. Midgley, "Immunotherapy for colorectal cancer: Potential application in an adjuvant setting", SEMIN ONCOL, 27(5), 2000, pp. 132-137
70. Hoffman, DMJ; Gitlitz, BJ; Belldegrun, A; Figlin, RA
    Adoptive cellular therapy
    SEMINARS IN ONCOLOGY
    
    D.M.J. Hoffman et al., "Adoptive cellular therapy", SEMIN ONCOL, 27(2), 2000, pp. 221-233
71. Melief, CJM; Toes, REM; Medema, JP; Van der Burg, SH; Ossendorp, F; Offringa, R
    Strategies for immunotherapy of cancer
    ADVANCES IN IMMUNOLOGY, VOL 75
    
    C.J.M. Melief et al., "Strategies for immunotherapy of cancer", ADV IMMUNOL, 75, 2000, pp. 235-282
72. Braathen, LR; Hunger, RE; Brand, CU
    Immunotherapy of malignant melanoma
    ZENTRALBLATT FUR CHIRURGIE
    
    L.R. Braathen et al., "Immunotherapy of malignant melanoma", ZBL CHIR, 125(10), 2000, pp. 806-809
73. Seo, N; Tokura, Y; Nishijima, T; Hashizume, H; Furukawa, F; Takigawa, M
    Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    
    N. Seo et al., "Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis", P NAS US, 97(1), 2000, pp. 371-376
74. Zoller, M; Matzku, S
    Vaccination: A future modality of cancer therapy
    DRUGS OF TODAY
    
    M. Zoller e S. Matzku, "Vaccination: A future modality of cancer therapy", DRUGS TODAY, 36(8), 2000, pp. 557-581
75. Gambotto, A; Cicinnati, V; Robbins, PD
    Genetic approaches for biologic therapy of cancer
    DRUGS OF TODAY
    
    A. Gambotto et al., "Genetic approaches for biologic therapy of cancer", DRUGS TODAY, 36(1), 2000, pp. 25-39
76. Cochlovius, B; Stassar, M; Christ, O; Raddrizzani, L; Hammer, J; Mytilineos, I; Zoller, M
    In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program
    JOURNAL OF IMMUNOLOGY
    
    B. Cochlovius et al., "In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program", J IMMUNOL, 165(8), 2000, pp. 4731-4741
77. Warren, TL; Bhatia, SK; Acosta, AM; Dahle, CE; Ratliff, TL; Krieg, AM; Weiner, GJ
    APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC classI-restricted T cells
    JOURNAL OF IMMUNOLOGY
    
    T.L. Warren et al., "APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC classI-restricted T cells", J IMMUNOL, 165(11), 2000, pp. 6244-6251
78. Davila, E; Celis, E
    Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity
    JOURNAL OF IMMUNOLOGY
    
    E. Davila e E. Celis, "Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity", J IMMUNOL, 165(1), 2000, pp. 539-547
79. Baxevanis, CN; Voutsas, IF; Tsitsilonis, OE; Gritzapis, AD; Sotiriadou, R; Papamichail, M
    Tumor-specific CD4(+) T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor
    JOURNAL OF IMMUNOLOGY
    
    C.N. Baxevanis et al., "Tumor-specific CD4(+) T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor", J IMMUNOL, 164(7), 2000, pp. 3902-3912
80. Sun, YS; Song, MX; Stevanovic, S; Jankowiak, C; Paschen, A; Rammensee, HG; Schadendorf, D
    Identification of a new HLA-A*0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen
    INTERNATIONAL JOURNAL OF CANCER
    
    Y.S. Sun et al., "Identification of a new HLA-A*0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen", INT J CANC, 87(3), 2000, pp. 399-404
81. Noppen, C; Levy, F; Burri, L; Zajac, P; Remmel, E; Schaefer, C; Luscher, U; Heberer, M; Spagnoli, GC
    Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2
    INTERNATIONAL JOURNAL OF CANCER
    
    C. Noppen et al., "Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2", INT J CANC, 87(2), 2000, pp. 241-246
82. Roth, MD; Gitlitz, BJ; Kiertscher, SM; Park, AN; Mendenhall, M; Moldawer, N; Figlin, RA
    Granulocyte macrophage colony-stimulating factor and interleukin 4 enhancethe number and antigen-presenting activity of circulating CD14(+) and CD83(+) cells in cancer patients
    CANCER RESEARCH
    
    M.D. Roth et al., "Granulocyte macrophage colony-stimulating factor and interleukin 4 enhancethe number and antigen-presenting activity of circulating CD14(+) and CD83(+) cells in cancer patients", CANCER RES, 60(7), 2000, pp. 1934-1941
83. Gautier, F; Irminger-Finger, I; Gregoire, M; Meflah, K; Harb, J
    Identification of an apoptotic cleavage product of BARD1 as an autoantigen: A potential factor in the antitumoral response mediated by apoptotic bodies
    CANCER RESEARCH
    
    F. Gautier et al., "Identification of an apoptotic cleavage product of BARD1 as an autoantigen: A potential factor in the antitumoral response mediated by apoptotic bodies", CANCER RES, 60(24), 2000, pp. 6895-6900
84. Lu, J; Celis, E
    Use of two predictive algorithms of the World Wide Web for the identification of tumor-reactive T-cell epitopes
    CANCER RESEARCH
    
    J. Lu e E. Celis, "Use of two predictive algorithms of the World Wide Web for the identification of tumor-reactive T-cell epitopes", CANCER RES, 60(18), 2000, pp. 5223-5227
85. Kobayashi, H; Wood, M; Song, YS; Appella, E; Celis, E
    Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen
    CANCER RESEARCH
    
    H. Kobayashi et al., "Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen", CANCER RES, 60(18), 2000, pp. 5228-5236
86. Santin, AD
    Lymph node metastases - The importance of the microenvironment
    CANCER
    
    A.D. Santin, "Lymph node metastases - The importance of the microenvironment", CANCER, 88(1), 2000, pp. 175-179
87. Liu, YJ; Blom, B
    Introduction: TH2-inducing DC2 for immunotherapy
    BLOOD
    
    Y.J. Liu e B. Blom, "Introduction: TH2-inducing DC2 for immunotherapy", BLOOD, 95(8), 2000, pp. 2482-2483
88. Pinilla-Ibarz, J; Cathcart, K; Korontsvit, T; Soignet, S; Bocchia, M; Caggiano, J; Lai, L; Jimenez, J; Kolitz, J; Scheinberg, DA
    Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
    BLOOD
    
    J. Pinilla-Ibarz et al., "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses", BLOOD, 95(5), 2000, pp. 1781-1787
89. Fleischhauer, K; Gattinoni, L; Lietti, G; Zino, E; Bordignon, C; Traversari, C
    Identification of tumor antigen-specific cytotoxic T lymphocytes cross-recognizing allogeneic major histocompatibility class I molecules
    TISSUE ANTIGENS
    
    K. Fleischhauer et al., "Identification of tumor antigen-specific cytotoxic T lymphocytes cross-recognizing allogeneic major histocompatibility class I molecules", TISSUE ANTI, 56(1), 2000, pp. 19-29
90. Horig, H; Kaufman, HL
    Current issues in cancer vaccine development
    CLINICAL IMMUNOLOGY
    
    H. Horig e H.L. Kaufman, "Current issues in cancer vaccine development", CLIN IMMUNO, 92(3), 1999, pp. 211-223
91. Schirmbeck, R; Reimann, J
    Enhancing the immunogenicity of exogenous hepatitis B surface antigen-based vaccines for MHC-I-restricted T cells
    BIOLOGICAL CHEMISTRY
    
    R. Schirmbeck e J. Reimann, "Enhancing the immunogenicity of exogenous hepatitis B surface antigen-based vaccines for MHC-I-restricted T cells", BIOL CHEM, 380(3), 1999, pp. 285-291
92. Bilbao, G; Contreras, JL; Curiel, DT
    Advances in cancer gene therapy
    EXPERT OPINION ON THERAPEUTIC PATENTS
    
    G. Bilbao et al., "Advances in cancer gene therapy", EXPERT OP T, 9(6), 1999, pp. 711-736
93. Kammula, US; Marincola, FM
    Cancer immunotherapy: Is there real progress at last?
    BIODRUGS
    
    U.S. Kammula e F.M. Marincola, "Cancer immunotherapy: Is there real progress at last?", BIODRUGS, 11(4), 1999, pp. 249-260
94. O'Donnell, DM; Patel, PM; Sousa, CRE
    Gene manipulation in the induction of anti-tumor immunity
    GENE THERAPY
    
    D.M. O'Donnell et al., "Gene manipulation in the induction of anti-tumor immunity", GENE THER, 6(11), 1999, pp. 1796-1797
95. de Cerio, ALD; Casares, N; Lasarte, JJ; Sarobe, P; Perez-Mediavilla, LA; Ruiz, M; Prieto, J; Borras-Cuesta, F
    T(h)1 but not T(h)0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides
    INTERNATIONAL IMMUNOLOGY
    
    A.L.D. de Cerio et al., "T(h)1 but not T(h)0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides", INT IMMUNOL, 11(12), 1999, pp. 2025-2033
96. Sun, YS; Paschen, A; Schadendorf, D
    Cells-based vaccination against melanoma - background, preliminary results, and perspective
    JOURNAL OF MOLECULAR MEDICINE-JMM
    
    Y.S. Sun et al., "Cells-based vaccination against melanoma - background, preliminary results, and perspective", J MOL MED-J, 77(8), 1999, pp. 593-608
97. Carbone, DP
    Molecular modalities in the treatment of lung cancer
    ONCOLOGY-NEW YORK
    
    D.P. Carbone, "Molecular modalities in the treatment of lung cancer", ONCOLOGY-NY, 13(10), 1999, pp. 142-147
98. Levy, Y
    Antigen presentation: physiology and perversion
    M S-MEDECINE SCIENCES
    
    Y. Levy, "Antigen presentation: physiology and perversion", M S-MED SCI, 15(8-9), 1999, pp. 921-922
99. Zitvogel, L; Faure, F
    Cancer immunotherapy
    M S-MEDECINE SCIENCES
    
    L. Zitvogel e F. Faure, "Cancer immunotherapy", M S-MED SCI, 15(8-9), 1999, pp. 939-949
100. Bagot, M; Boumsell, L; Bensussan, A
     Contribution of immunotherapy for the treatment of T-cell lymphomas of theskin
     PRESSE MEDICALE
     
     M. Bagot et al., "Contribution of immunotherapy for the treatment of T-cell lymphomas of theskin", PRESSE MED, 28(34), 1999, pp. 1911-1916